Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 220-225 , November 2009

18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer

  • Hui Wang

      Affiliations

    • Service of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland
    • ,
  • Hansjörg Vees

      Affiliations

    • Service of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland
    • ,
  • Raymond Miralbell

      Affiliations

    • Service of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland
    • ,
  • Michael Wissmeyer

      Affiliations

    • Service of Nuclear Medicine, Geneva University Hospital, Geneva, Switzerland
    • ,
  • Charles Steiner

      Affiliations

    • Service of Nuclear Medicine, Geneva University Hospital, Geneva, Switzerland
    • ,
  • Osman Ratib

      Affiliations

    • Service of Nuclear Medicine, Geneva University Hospital, Geneva, Switzerland
    • ,
  • Srinivasan Senthamizhchelvan

      Affiliations

    • Service of Nuclear Medicine, Geneva University Hospital, Geneva, Switzerland
    • ,
  • Habib Zaidi

      Affiliations

    • Service of Nuclear Medicine, Geneva University Hospital, Geneva, Switzerland
    • Geneva Neuroscience Center, Geneva University, Geneva, Switzerland
    • Corresponding Author InformationCorresponding author. Address: Division of Nuclear Medicine, Geneva University Hospital, CH-1211 Geneva 4, Switzerland.

Received 24 March 2009 ,Revised 25 August 2009 ,Accepted 27 August 2009.

References 

  1. Kupelian PA, Buchsbaum JC, Patel C, et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys. 2002;52:704–711
  2. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57:915–928
  3. Grossfeld GD, Stier DM, Flanders SC, et al. Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. J Urol. 1998;160:1398–1404
  4. Nguyen PL, D’Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007;110:1417–1428
  5. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology. 2002;60:264–269
  6. Arora R, Koch MO, Eble JN, et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer. 2004;100:2362–2366
  7. Huang WC, Kuroiwa K, Serio AM, et al. The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncological efficacy of salvage ablative therapies. J Urol. 2007;177:1324–1329quiz 1591
  8. Pucar D, Hricak H, Shukla-Dave A, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007;69:62–69
  9. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med. 2008;49:2031–2041
  10. Cimitan M, Bortolus R, Morassut S, et al. [(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387–1398
  11. Husarik DB, Miralbell R, Dubs M, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:253–263
  12. Pouliot J, Kim Y, Lessard E, et al. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys. 2004;59:1196–1207
  13. van Lin ENJT, Fütterer JJ, Heijmink SWTPJ, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys. 2006;65:291–303
  14. Zaidi H, Vees H, Wissmeyer M. Molecular PET/CT imaging-guided radiation therapy treatment planning. Acad Radiol. 2009;16:1108–1133
  15. Steiner C, Vees H, Zaidi H, et al. Three-phase (18)F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin. 2009;48:1–9
  16. Zaidi H, El Naqa I. PET-guided delineation of radiation therapy treatment volumes: A review of image segmentation techniques. Submitted.
  17. Yaremko B, Riauka T, Robinson D, et al. Thresholding in PET images of static and moving targets. Phys Med Biol. 2005;50:5969–5982
  18. Hong R, Halama J, Bova D, Sethi A, Emami B. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys. 2007;67:720–726
  19. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005;235:623–628
  20. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002;43:92–96Erratum in J Nucl Med 43(4):509
  21. Graves EE, Quon A, Loo BW. RT_Image: an open-source tool for investigating PET in radiation oncology. Technol Cancer Res Treat. 2007;6:111–121
  22. Vees H, Senthamizhchelvan S, Miralbell R, et al. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging. 2009;36:182–193
  23. Daisne J-F, Sibomana M, Bol A, et al. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol. 2003;69:247–250
  24. Coakley FV, Teh HS, Qayyum A, et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology. 2004;233:441–448
  25. Oehr P, Bouchelouche K. Imaging of prostate cancer. Curr Opin Oncol. 2007;19:259–264
  26. Caldwell CB, Mah K, Ung YC, et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys. 2001;51:923–931
  27. van Baardwijk A, Bosmans G, Boersma L, et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys. 2007;68:771–778
  28. Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol. 2005;173:1156–1160
  29. Giraud P, Elles S, Helfre S, et al. Conformal radiotherapy for lung cancer: different delineation of the gross tumor volume (GTV) by radiologists and radiation oncologists. Radiother Oncol. 2002;62:27–36
  30. Schinagl DA, Vogel WV, Hoffmann AL, et al. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:1282–1289
  31. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology. 2004;233:93–100
  32. Chun FK, Briganti A, Jeldres C, et al. Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer. 2007;43:536–543
  33. Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M. Is tumor volume an independent prognostic factor in clinically localized prostate cancer?. J Urol. 2004;172:508–511
  34. Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 1999;44:921–929

PII: S0167-8140(09)00471-X

doi: 10.1016/j.radonc.2009.08.037

Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 220-225 , November 2009

Article Tools

* Image Usage & Resolution